The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19.

Marlies de Ligt Matthijs K C HesselinkJohanna JorgensenJohan W E JockenEllen E Blaak Gijs H Goossens

Published in: Obesity (Silver Spring, Md.) (2021)

Given the pivotal role of ACE2 in SARS-CoV-2 spread and the clinical outcomes in COVID-19 patients, the data suggest that the putative beneficial effects of angiotensin II type 1 receptor blockers on the clinical outcomes of patients with COVID-19 may not be mediated through altered ACE2 expression in abdominal subcutaneous AT.

Keyphrases

angiotensin ii
angiotensin converting enzyme
sars cov
vascular smooth muscle cells
respiratory syndrome coronavirus
poor prognosis
binding protein
coronavirus disease
big data
machine learning
deep learning